MediWound misses Q3 revenue estimates

Reuters11-20

MediWound misses Q3 revenue estimates

Overview

MediWound Q3 2025 revenue up 23% yr/yr but missed analyst expectations
Adjusted EBITDA loss for Q3 beats analyst estimates
Company strengthens balance sheet with $30 mln equity financing

Outlook

MediWound expects full operational capacity for NexoBrid facility by year-end 2025
Company plans to initiate EscharEx trial for diabetic foot ulcers in H2 2026
Peak sales opportunity for EscharEx estimated at $831 mln

Result Drivers

REVENUE GROWTH - Q3 revenue increased 23% yr/yr, driven by higher development service revenue from U.S. DoD contracts
EXPANDED CAPACITY - Completion of commissioning for expanded NexoBrid facility to increase production capacity sixfold by year-end 2025

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q3 Revenue	Miss	$5.40 mln	$6.65 mln (6 Analysts)
Q3 EPS		-$0.24
Q3 Net Income		-$2.70 mln
Q3 Adjusted EBITDA	Beat	-$5.40 mln	-$10.08 mln (2 Analysts)
Q3 Gross Profit		$900,000
Q3 Operating Income		-$6.50 mln

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Mediwound Ltd is $30.50, about 41.4% above its November 19 closing price of $17.86

Press Release: ID:nGNX4Lq6RT

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2584136738?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-20 20:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2584136738","market":"nz","top_or_hot":-1,"title":"MediWound misses Q3 revenue estimates","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>MediWound misses Q3 revenue estimates</title></head><body><p><span>Overview</span></p><ul><li><p>MediWound Q3 2025 revenue up 23% yr/yr but missed analyst expectations</p></li><li><p>Adjusted EBITDA loss for Q3 beats analyst estimates</p></li><li><p>Company strengthens balance sheet with $30 mln equity financing</p></li></ul><p><span>Outlook</span></p><ul><li><p>MediWound expects full operational capacity for NexoBrid facility by year-end 2025</p></li><li><p>Company plans to initiate EscharEx trial for diabetic foot ulcers in H2 2026</p></li><li><p>Peak sales opportunity for EscharEx estimated at $831 mln</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>REVENUE GROWTH - Q3 revenue increased 23% yr/yr, driven by higher development service revenue from U.S. DoD contracts</p></li><li><p>EXPANDED CAPACITY - Completion of commissioning for expanded NexoBrid facility to increase production capacity sixfold by year-end 2025</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Revenue</p></td><td><p>Miss</p></td><td><p>$5.40 mln</p></td><td><p>$6.65 mln (6 Analysts)</p></td></tr><tr><td><p>Q3 EPS</p></td><td></td><td><p>-$0.24</p></td><td></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>-$2.70 mln</p></td><td></td></tr><tr><td><p>Q3 Adjusted EBITDA</p></td><td><p>Beat</p></td><td><p>-$5.40 mln</p></td><td><p>-$10.08 mln (2 Analysts)</p></td></tr><tr><td><p>Q3 Gross Profit</p></td><td></td><td><p>$900,000</p></td><td></td></tr><tr><td><p>Q3 Operating Income</p></td><td></td><td><p>-$6.50 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 6 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the pharmaceuticals peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for Mediwound Ltd is $30.50, about 41.4% above its November 19 closing price of $17.86</p></li></ul><p>Press Release: <span>ID:nGNX4Lq6RT</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>MediWound misses Q3 revenue estimates</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMediWound misses Q3 revenue estimates\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-20 20:08</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>MediWound misses Q3 revenue estimates</title></head><body><p><span>Overview</span></p><ul><li><p>MediWound Q3 2025 revenue up 23% yr/yr but missed analyst expectations</p></li><li><p>Adjusted EBITDA loss for Q3 beats analyst estimates</p></li><li><p>Company strengthens balance sheet with $30 mln equity financing</p></li></ul><p><span>Outlook</span></p><ul><li><p>MediWound expects full operational capacity for NexoBrid facility by year-end 2025</p></li><li><p>Company plans to initiate EscharEx trial for diabetic foot ulcers in H2 2026</p></li><li><p>Peak sales opportunity for EscharEx estimated at $831 mln</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>REVENUE GROWTH - Q3 revenue increased 23% yr/yr, driven by higher development service revenue from U.S. DoD contracts</p></li><li><p>EXPANDED CAPACITY - Completion of commissioning for expanded NexoBrid facility to increase production capacity sixfold by year-end 2025</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Revenue</p></td><td><p>Miss</p></td><td><p>$5.40 mln</p></td><td><p>$6.65 mln (6 Analysts)</p></td></tr><tr><td><p>Q3 EPS</p></td><td></td><td><p>-$0.24</p></td><td></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>-$2.70 mln</p></td><td></td></tr><tr><td><p>Q3 Adjusted EBITDA</p></td><td><p>Beat</p></td><td><p>-$5.40 mln</p></td><td><p>-$10.08 mln (2 Analysts)</p></td></tr><tr><td><p>Q3 Gross Profit</p></td><td></td><td><p>$900,000</p></td><td></td></tr><tr><td><p>Q3 Operating Income</p></td><td></td><td><p>-$6.50 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 6 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the pharmaceuticals peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for Mediwound Ltd is $30.50, about 41.4% above its November 19 closing price of $17.86</p></li></ul><p>Press Release: <span>ID:nGNX4Lq6RT</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MDWD","symbol_name":"MediWound Ltd.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251120:nL1N3WW0G7:1","article_id":"2584136738","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2584136738","pubTimestamp":1763640535,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"MediWound misses Q3 revenue estimatesOverviewMediWound Q3 2025 revenue up 23% yr/yr but missed analyst expectationsAdjusted EBITDA loss for Q3 beats analyst estimatesCompany strengthens balance sheet ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MDWD":"MediWound Ltd.","BK4007":"制药"},"translate_title":"MediWound未达到第三季度收入预期","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MDWD":0.9},"content_text":"MediWound misses Q3 revenue estimatesOverviewMediWound Q3 2025 revenue up 23% yr/yr but missed analyst expectationsAdjusted EBITDA loss for Q3 beats analyst estimatesCompany strengthens balance sheet with $30 mln equity financingOutlookMediWound expects full operational capacity for NexoBrid facility by year-end 2025Company plans to initiate EscharEx trial for diabetic foot ulcers in H2 2026Peak sales opportunity for EscharEx estimated at $831 mlnResult DriversREVENUE GROWTH - Q3 revenue increased 23% yr/yr, driven by higher development service revenue from U.S. DoD contractsEXPANDED CAPACITY - Completion of commissioning for expanded NexoBrid facility to increase production capacity sixfold by year-end 2025Key DetailsMetricBeat/MissActualConsensus EstimateQ3 RevenueMiss$5.40 mln$6.65 mln (6 Analysts)Q3 EPS-$0.24Q3 Net Income-$2.70 mlnQ3 Adjusted EBITDABeat-$5.40 mln-$10.08 mln (2 Analysts)Q3 Gross Profit$900,000Q3 Operating Income-$6.50 mlnAnalyst CoverageThe current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 6 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"The average consensus recommendation for the pharmaceuticals peer group is \"buy\"Wall Street's median 12-month price target for Mediwound Ltd is $30.50, about 41.4% above its November 19 closing price of $17.86Press Release: ID:nGNX4Lq6RTFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2584136738","isCrawlerRequest":true}